trending Market Intelligence /marketintelligence/en/news-insights/trending/0UhoRVBe47irelYpzDaIAg2 content esgSubNav
In This List

Argos Therapeutics, Personalis enter research agreement

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Argos Therapeutics, Personalis enter research agreement

Argos Therapeutics Inc. entered a strategic research agreement with Personalis Inc. focused on genomics solutions for immuno-oncology, cancer and genetic disease.

Personalis will serve as the primary genomic analysis service provider to support ongoing research efforts to demonstrate that Argos' lead product candidate, rocapuldencel-T, specifically targets patient-specific neoantigens without having to identify them first.

Argos will utilize the Personalis' ACE ImmunoID sequencing platform to evaluate tumor samples collected during clinical development of its tumor-specific dendritic cell technology to treat renal cell carcinoma.

Rocapuldencel-T is being evaluated in a phase 3 clinical trial for the treatment of metastatic renal cell carcinoma. It is also s being studied in phase 2 investigator-initiated clinical trials as neoadjuvant therapy for renal cell carcinoma and for the treatment of nonsmall cell lung cancer.